Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension

Shots:

• BI has launched Semintra (4mg/mL) in the EU for the treatment of systemic hypertension in cats
• Semintra has shown clinical efficacy in reducing proteinuria & blood pressure, which may help restore kidney balance while also promoting cat’s appetite, activity levels, & QoL
• Semintra (QD) is a telmisartan solution administered orally or on top of food using a mL-calibrated syringe. The US FDA has already approved Semintra it in 2013 & 2018 for feline proteinuria & hypertension, respectively

Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim

Related News:- Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com